Robert Kirkman, MD
Dr. Kirkman is Executive Chair of Trillium Therapeutics. He was President and Chief Executive Officer of Oncothyreon from September 2006 until January 2016.
From 2005 to 2006, he was acting President and Chief Executive Officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceutical companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was Chief Business Officer and Vice President of Xcyte. From 1998 to 2003, Dr. Kirkman was Vice President, Business Development and Corporate Communications of Protein Design Labs, a biopharmaceutical company. Dr. Kirkman holds a MD degree from Harvard Medical School and a BA in economics from Yale University.